Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention
- 1Herz-Zentrum, Bad Krozingen, Germany
- 2University Hospital Basel, Department of Internal Medicine, Basel, Switzerland
- Correspondence to:
Dr Christian Mueller
Department of Internal Medicine, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland;
- Accepted 12 November 2003
Objectives: To quantify the impact of baseline renal function on in-hospital and long term mortality in patients with unstable angina/non-ST elevation acute myocardial infarction (UA/NSTEMI) treated with a very early invasive strategy.
Design: Prospective cohort study of 1400 consecutive patients with UA/NSTEMI undergoing coronary angiography and subsequent coronary stenting of the culprit lesion as the primary revascularisation strategy within 24 hours of admission. Patients were stratified according to calculated glomerular filtration rate (GFR) on admission.
Results: In-hospital mortality was 0% among patients with a GFR ⩾ 130 ml/min/1.73 m2, 0.4% with a GFR of 90–129 ml/min/1.73 m2, 2.6% with a GFR of 60–89 ml/min/1.73m2, and 5.1% with a GFR of < 60 ml/min/1.73 m2. Cumulative three year survival rates were 92.6%, 95.5%, 91.9%, and 76.8%, respectively. Patients with a GFR of < 60 ml/min/1.73 m2 were four times more likely to die in hospital (hazard ratio (HR) 4.0, 95% confidence interval (CI) 1.8 to 9.1; p = 0.001) and four times more likely to die during long term follow up (HR 4.0, 95% CI 2.5 to 6.4; p < 0.001). After adjusting for potential confounders, a GFR of < 60 ml/min/1.73 m2 remained a strong independent predictor of long term mortality (HR 2.6, 95% CI 1.5 to 4.5; p = 0.001).
Conclusions: Baseline renal function is a strong independent predictor of in-hospital and long term mortality after UA/NSTEMI treated with very early revascularisation.
- BARI, bypass angioplasty revascularisation investigation
- CABG, coronary artery bypass grafting
- CI, confidence interval
- CK, creatine kinase
- GFR, glomerular filtration rate
- PCI, percutaneous coronary intervention
- TACTICS-TIMI 18, treat angina with Aggrastat and determine cost of therapy with an invasive or conservative strategy–thrombolysis in myocardial infarction 18
- UA/NSTEMI, unstable angina/non-ST segment elevation myocardial infarction
About four million patients attend emergency departments in Europe each year with chest pain and suspected unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI).1 However, risk stratification is often particularly challenging in UA/NSTEMI. Early coronary angiography and revascularisation has been proposed as a novel potentially superior management strategy for these patients.2–5 Current practice guidelines for the management of patients with UA/NSTEMI recommend an early invasive strategy for most patients.2,6 Predictors of long term mortality in UA/NSTEMI treated with an early invasive strategy remain to be established.
The implications of chronic kidney disease for cardiovascular outcomes have attained increasing recognition.7,8 Large registries including predominantly patients with ST elevation myocardial infarction treated with thrombolytic agents suggested that baseline renal function measured as serum creatinine or estimated creatinine clearance is a predictor of mortality.9–11 McCullough and colleagues12 confirmed this observation among patients admitted to a single coronary care unit. In these studies, patients were primarily treated conservatively with anti-ischaemic and antithrombotic medication unless ST elevation was evident on the admission ECG. Coronary angiography was performed only after “cooling down” with medical treatment and was restricted to patients with recurrent ischaemia.
Thus, the present study had two aims: firstly, to explore the association between baseline renal function and mortality after UA/NSTEMI in a large cohort of consecutive unselected patients treated uniformly very early and predominantly with percutaneous coronary intervention (PCI); and secondly, to test whether this latest, aggressive treatment is both safe and efficacious for patients presenting with renal dysfunction.
From January 1996 to December 1999, consecutive patients admitted to our centre with UA/NSTEMI were treated with a very early invasive strategy. Patients undergoing coronary angiography for symptoms of myocardial ischaemia occurring at rest (Braunwald class IIIB unstable angina) were eligible for inclusion in this study.13 We excluded patients with de novo angina pectoris on exertion or worsening angina during exertion only (Braunwald class 1A–C), patients with persistent ST elevation, and patients with postinfarction angina (Braunwald class 1C, 2C, or 3C), patients in whom angiography was not performed because of patient refusal (n = 6) or extremely severe concomitant disease (n = 9 with severe dementia or advanced malignancy), and patients with no serum creatinine determined on admission (n = 50). Therefore, this study included 96% (1400 of 1465) of the total number of consecutive patients with UA/NSTEMI admitted to our centre and 99% of those with serum creatinine available. These include patients with end stage renal disease on dialysis, high bleeding risks, and prior stroke. The study was carried out according to the principles of the Declaration of Helsinki and was approved by the institutional review board. Informed consent was obtained from all participating patients. At hospital discharge all patients were prescribed a low cholesterol diet and statins were recommended to achieve a low density lipoprotein cholesterol concentration below 3.0 mmol/l during follow up. Angiotensin converting enzyme inhibitors were given to all patients with renal dysfunction, diabetes, or prior myocardial infarction unless they were considered hypovolaemic.
Renal function and glomerular filtration rate
The glomerular filtration rate (GFR) is the best measure of overall kidney function.14–16 We calculated GFR with the use of the abbreviated modification of diet in renal disease study equation14–16: GFR (in ml/min/1.73 m2 of body surface area) = 186 × (serum creatinine in mg/dl)−1.154 × (age in years)−0.203 × 0.742 for female patients and × 1.210 for black patients. This equation is based on data from Levey and colleagues15 on 1628 patients with 558 in the validation set.
A venous blood specimen for serum creatinine determination was drawn on admission. All samples were analysed in a central laboratory with the use of an enzymatic kit (CREA plus, Boehringer Mannheim Systems, Mannheim, Germany). Patients were divided into groups according to their renal function as assessed by GFR (National Kidney Foundation kidney disease outcomes quality initiative stages).14–16
Very early revascularisation
Patients with persistent chest pain underwent immediate coronary angiography. Among patients asymptomatic while taking medical treatment, coronary angiography was performed within 24 hours of admission. Whenever possible, coronary stenting of the culprit lesion was done immediately after angiography. Stenting was not restricted to patients with one and two vessel disease but was also favoured for patients with three vessel disease with suitable lesions. The median time interval from admission to PCI was five hours. If revascularisation was indicated but PCI was not considered the optimal treatment option (unprotected left main disease, diffuse three vessel disease), patients were scheduled for urgent coronary artery bypass grafting (CABG).
All patients were scheduled for outpatient visits at six months. In addition, patients were contacted by questionnaire in September 2000, nearly five years after enrolment of the first patient. For patients reporting cardiac symptoms, at least one clinical and ECG examination was performed in the outpatient clinic or by the referring physician. All information derived from contingent hospital readmission records or provided by the referring physician or by the outpatient clinic was reviewed and entered on to the computer database.
End points and statistical analysis
The pre-specified primary end point was defined as death from all causes occurring in hospital or during follow up. As secondary end points we assessed non-fatal myocardial infarction and the composite of death and non-fatal myocardial infarction. Myocardial infarction was defined as typical chest pain at rest followed by an increase in creatine kinase concentration (CK and CK-MB beyond twice the upper limit of normal and five times the upper limit of normal after CABG) or new Q waves on the ECG. To meet this end point criterion, patients who had initially presented with myocardial infarction had to have new ST segment changes and an increase in CK of at least 50% over the previous trough concentration in at least two samples reaching at least three times the upper limit of normal. ECGs were recorded for all patients directly after PCI or CABG and in the following morning. In addition, cardiac markers (CK and CK-MB) were determined 8–24 hours after the intervention and additionally whenever ischaemic symptoms developed.
The statistical analyses were done with the SPSS/PC (version 11.0, SPSS Inc, Chicago, Illinois, USA) software package. Discrete variables were expressed as percentage (95% confidence interval (CI)) and continuous variables as mean (95% CI). A significance level of 0.05 was used. Comparisons were made by analysis of variance for independent samples and χ2 tests as appropriate. All hypothesis testing was two tailed. Cox proportional hazards regression analysis was used as the appropriate multivariate method for adjustment throughout. Multivariate Cox regression analysis was performed to identify independent predictors of death. All baseline clinical, laboratory, and angiographic variables were entered into the model. The cumulative survival curves were constructed with the use of the Kaplan-Meier method.
GFR was estimated for 1400 consecutive patients. The median GFR was 88 ml/min/1.73 m2 of body surface area (mean 89 ml/min/1.73 m2). Table 1 describes the baseline, demographic, clinical, angiographic, and procedural characteristics of the cohort, divided into groups according to their renal function as assessed by GFR (National Kidney Foundation kidney disease outcomes quality initiative stages).14–16
Table 1 shows the differences in baseline characteristics between these groups. Patients with a GFR < 60 ml/min/1.73 m2 of body surface area (kidney disease outcomes quality initiative stage 3–5) were older, more often had prior myocardial infarction, diabetes, and hypertension, and less often were smokers. In addition, these patients more often required mechanical cardiopulmonary resuscitation or defibrillation before admission and more often had new ST segment depression, increased troponin T, and increased white blood cell count on admission than did patients in the other GFR ranges. Coronary angiography was performed in all 1400 patients and showed that the extent of coronary artery disease was significantly more advanced in patients with a GFR < 60 ml/min/1.73 m2 of body surface area.
PCI was the predominant revascularisation procedure applied in all ranges of GFR. About 70% of patients actually underwent revascularisation. The overall PCI to CABG ratio was 4:1, with the highest CABG rate among patients with a GFR < 60 ml/min/1.73 m2 of body surface area.
Eighty two deaths and 59 non-fatal myocardial infarctions occurred during a mean follow up of 20 months (95% CI 19 to 21 months). The mean interval until last patient contact or patient death was 21 months in the groups with GFR ⩾ 130 ml/min/1.73 m2 (2177 person-months) and GFR 90–129 ml/min/1.73 m2 (11293 person-months), 20 months with GFR 60–89 ml/min/1.73 m2 (11443 person-months), and 16 months with GFR < 60 ml/min/1.73 m2 (2886 person-months). The majority of deaths were from cardiac causes. In-hospital mortality was significantly higher among patients with a GFR < 60 ml/min/1.73 m2 of body surface area than among patients with higher GFR (table 2). The rate was 0% with GFR ⩾ 130 ml/min/1.73 m2, 0.4% with GFR 90–129 ml/min/1.73 m2, 2.6% with GFR 60–89 ml/min/1.73 m2, and 5.1% with GFR < 60 ml/min/1.73 m2 (hazard ratio (HR) 4.0, 95% CI 1.8 to 9.1; p = 0.001). The incidence of in-hospital non-fatal myocardial infarction was low and not different between the GFR ranges.
During total follow up, mortality was significantly higher among patients with a GFR < 60 ml/min/1.73 m2 of body surface area than among patients with higher GFR (table 2). Relative to patients in the higher GFR ranges, patients with GFR < 60 ml/min/1.73 m2 were four times more likely to die during follow up (HR 4.0; p < 0.001). The incidence of non-fatal myocardial infarction during total follow up was not different between the GFR ranges. Kaplan-Meier survival analysis showed cumulative three year survival rates of 92.6% with GFR ⩾ 130 ml/min/1.73 m2, 95.5% with GFR 90–129 ml/min/1.73 m2, 91.9% with GFR 60–89 ml/min/1.73 m2, and 76.8% with GFR < 60 ml/min/1.73 m2 (p < 0001 by log rank) (fig 1). The cumulative three year survival rate was 96.9% among patients with creatinine concentrations on admission not available.
The predictive value of GFR was irrespective of the presence or absence of diabetes (fig 2). The cumulative three year survival rates among non-diabetic and diabetic patients with GFR < 60 ml/min/1.73 m2 were 78.9% and 74.7%, respectively (HR for diabetes 2.0, 95% CI 0.9 to 4.4; p = 0.09). Non-diabetic patients with GFR < 60 ml/min/1.73 m2 were at higher risk of death than were diabetic patients with GFR > 60 ml/min/1.73 m2 (HR 1.9, 95% CI 1.0 to 3.8; p = 0.058).
Renal function was predictive of long term mortality irrespective of the revascularisation method applied. Patients with a GFR < 60 ml/min/1.73 m2 of body surface area had an HR of 3.6 (95% CI 1.7 to 7.6; p = 0.001) if receiving PCI and an HR of 3.9 (95% CI 1.9 to 8.1; p < 0.001) if receiving CABG. HR was 2.9 (95% CI 0.9 to 8.8; p = 0.065) for those being managed without revascularisation and with medical treatment only. Among patients without a ⩾ 50% stenosis in the epicardial segments of the coronary vessels (n = 173) and therefore presumably with either thromboembolic, vasospastic, microvascular, or non-cardiac disease, the event rate during follow up was very low. Only four patients died or experienced non-fatal myocardial infarction. Therefore, this study did not have sufficient statistical power to assess the predictive value of renal function in this subset of patients.
Together with calculated GFR, all baseline, demographic, clinical, and angiographic variables shown in table 1 were entered into a multivariate Cox regression analysis. After adjustment for these cofounders, a GFR < 60 ml/min/1.73 m2 of body surface area was found to be a strong independent predictor of long term mortality (HR 2.6; p = 0.001) (table 3). Of note, diabetes fell out of the predictive model when renal function was considered.
This large study of 1400 consecutive patients with UA/NSTEMI treated uniformly very early and predominantly with PCI confirmed baseline renal function as a strong independent predictor of in-hospital and long term mortality and thereby extends this important finding to this latest revascularisation strategy. With its universal availability, calculated GFR may serve as an inexpensive new tool for risk stratification in UA/NSTEMI. The increased risk of death with chronic kidney disease was independent of and additive to the risk associated with diabetes, in full agreement with an observation in CABG patients reported by the BARI (bypass angioplasty revascularisation investigation) investigators.17 Moreover, when diabetes and renal function were taken into consideration together, chronic kidney disease was the dominant risk factor. The adjusted HR for long term mortality was 2.6 for those with a GFR of < 60 ml/min/1.73 m2, whereas diabetes was no longer an independent predictor.
Among the explanations for why chronic kidney disease is such a potent risk factor for adverse outcomes in UA/NSTEMI, excess co-morbidity, less use of beneficial treatments for patients with chronic kidney disease, excess toxicity from conventional treatments used, and the unique pathobiology of the chronic kidney disease state seem to be the most decisive.8 Given the importance of the under use of cardioprotective treatments for patients with chronic kidney disease and the finding that low utilisation of reperfusion strategies contributed significantly to the poor prognosis of these patients in previous studies,10 this study appears particularly strong in that it is based on a prospective, consecutive, and unselected patient cohort and that a uniform revascularisation strategy was applied to all patients. These factors eliminate selection bias and ease the extrapolation of findings into clinical practice. Therefore, our data support the findings of the TACTICS-TIMI 18 (treat angina with Aggrastat and determine cost of therapy with an invasive or conservative strategy–thrombolysis in myocardial infarction 18) trial, where patients with a serum creatinine concentration of more than 2.5 mg/dl (221 μmol/l), a history of PCI or CABG within the preceding six months, factors associated with an increased risk of bleeding, cardiogenic shock, or severe systemic disorders were excluded.18 Moreover, the median time interval from admission to PCI was five hours in this study as compared with 25 hours in the invasive strategy of the TACTICS-TIMI 18 trial.18 Other particular features of the present study are the long term follow up and that the extent of coronary artery disease was quantified for all patients and entered into the multivariate analysis as a potential confounder.
Rationale for renal function as a predictor of outcome
Our results extend renal function as a powerful prognostic factor to an increasingly common disease treated with the latest revascularisation strategy. Very early revascularisation with predominantly PCI does not ameliorate the negative prognostic impact of renal function. The excess risk in patients with chronic kidney disease observed in previous studies can therefore not be sufficiently explained by lower efficacy and greater adverse events associated with thrombolytic treatment or extended periods of conservative antithrombotic and anti-ischaemic treatment. Our data support the importance of excess co-morbidities8 contributing to the inferior outcome for patients with impaired renal function. Firstly, patients with a GFR < 60 ml/min/1.73 m2 were older, they were more often diabetic, and coronary artery disease was more advanced with high rates of prior myocardial infarction and three vessel disease. Secondly, UA/NSTEMI was more severe in patients with a GFR < 60 ml/min/1.73 m2, as cardiopulmonary resuscitation, defibrillation, ST segment depression, and increased troponin T were seen more often than among patients in the higher GFR ranges. However, even after adjustment for these differences, the presence of a GFR < 60 ml/min/1.73 m2 was still predictive of long term mortality. Therefore, the unique pathobiology of the chronic kidney disease state8 seemed to contribute additionally to mortality during follow up.
This study was not designed to clarify the causal mediators of renal risk. Candidate mechanisms may include the presence of left ventricular hypertrophy, diastolic left ventricular dysfunction,7,19 pharmacological interactions, endothelial dysfunction,7 more aggressive atherosclerosis related to increases in serum homocysteine,20 increased sympathetic nerve activity,21 activated inflammatory and procoagulant pathways,22 and angiography related complications such as contrast nephropathy.23,24
Renal function in patients undergoing elective PCI
Recent studies have extended the correlation between renal insufficiency and clinical outcome to patients undergoing elective PCI.25–27 Chronic kidney disease was independently associated with mortality and other adverse events during and after PCI, in a dose dependent manner. Risk increased even when renal insufficiency was mild, with a doubling of mortality at one year.25
Unique risks and benefits of revascularisation among patients with chronic kidney disease
Coronary angiography, PCI, and CABG are associated with increased morbidity and mortality among patients with chronic kidney disease.7,17,25–29 This excess in risk is at least partly explained by the patients’ baseline characteristics. However, patients with chronic kidney disease are a high risk subgroup of patients with UA/NSTEMI and that is exactly the subset of patients who derive the maximum benefit from early revascularisation.2–6 Randomised trials specifically including patients with chronic kidney disease are lacking but would be highly desirable. The cumulative three year survival rate was 76.8% among patients with GFR < 60 ml/min/1.73 m2 in this study. This compares favourably with cohorts treated primarily medically.9–11 Although any comparison with historical controls has important limitations, our data along with those of others suggest that patients with chronic kidney disease fair better with early revascularisation.2,3,5,6,18 This is further supported by recent registry data suggesting that coronary stenting, which was used in our study as the predominant revascularisation procedure, has significantly improved procedural success rates and long term outcome for patients with chronic kidney disease.29
Firstly, serum creatinine was used for the calculation of GFR. This measure has limitations, as it may not be in a stable state and may reflect hydration status. Secondly, any equation for the calculation of GFR inherently includes age, and age has been a consistent factor in predicting cardiac outcome.
Renal function is a strong independent predictor of in-hospital and long term mortality in UA/NSTEMI treated with very early revascularisation. With its universal availability, GFR may serve as an inexpensive new tool for risk stratification in UA/NSTEMI.
This study was supported by research grants from the Novartis Foundation, the Krokus Foundation, and the University of Basel (to Dr Mueller).